Ultrasound-Guided Percutaneous Radiofrequency Ablation of Liver Metastasis From Ovarian Cancer: A Single-Center Initial Experience

Objective The aim of this study was to evaluate the feasibility, effectiveness, and safety of ultrasound-guided percutaneous radiofrequency ablation (RFA) for the treatment of liver metastasis from ovarian cancer (OC). Methods A retrospective review was performed on 11 patients (mean age, 53.0 ± 10.1 years) with 22 liver metastases (mean diameter, 2.0 ± 0.8 cm) from OC undergone RFA. Radiofrequency ablation was carried out with Starburst XL electrodes (RITA Medical System, Mountain View, CA) or Cool-tip electrodes (Cool-tip Systems; Valleylab, Boulder, CO). The tumor response, time to progression, and survival after RFA were assessed. Results Complete ablation was achieved for all lesions. The technique effectiveness was 100%. During the follow-up period, local tumor progression was observed in 1 (4.5%) of 22 lesions. The median time to progression was 8.0 months after RFA. Three patients died because of disease progression after 13, 18, and 24 months, respectively. The mean overall survival time after RFA was 53.1 ± 10.0 months, with the 1-, 3-, and 5-year overall survival rates of 100%, 61%, and 61%, respectively. No major complications were encountered. Conclusions Radiofrequency ablation as an alternative treatment strategy is feasible and effective for selected patients with liver metastasis from OC, providing a high rate of local tumor control.

[1]  M. Ribeiro,et al.  Complications of radiofrequency ablation of hepatic tumors: Frequency and risk factors. , 2014, World journal of hepatology.

[2]  Jaime Prat,et al.  2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. , 2014, Gynecologic oncology.

[3]  M. Reeves,et al.  Radiofrequency ablation of liver metastasis from ovarian adenocarcinoma: case report and literature review. , 2004, Gynecologic oncology.

[4]  Ming-de Lu,et al.  Long-Term Outcome of Percutaneous Ablation in Very Early-Stage Hepatocellular Carcinoma , 2011, Journal of Gastrointestinal Surgery.

[5]  W. Lau,et al.  A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.

[6]  M. Gore,et al.  Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. , 2002, The Lancet. Oncology.

[7]  J. Fleshman,et al.  Liver resection for colorectal metastases. , 2004, Annals of the Royal College of Surgeons of England.

[8]  A. Bryant,et al.  Optimal primary surgical treatment for advanced epithelial ovarian cancer. , 2011, The Cochrane database of systematic reviews.

[9]  D. Gervais,et al.  Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management. , 2006, AJR. American journal of roentgenology.

[10]  M. Piver,et al.  Metastatic patterns in histologic variants of ovarian cancer. An autopsy study , 1989, Cancer.

[11]  W. Lau,et al.  Percutaneous thermal ablation of medium and large hepatocellular carcinoma , 2009, Cancer.

[12]  Xuening Zhang,et al.  Percutaneous Cryoablation of Ovarian Cancer Metastasis to the Liver: Initial Experience in 13 Patients , 2015, International Journal of Gynecologic Cancer.

[13]  F. Xia,et al.  A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. , 2012, Journal of hepatology.

[14]  S. Dima,et al.  Long-term Survivors After Liver Resection for Ovarian Cancer Liver Metastases. , 2015, Anticancer research.

[15]  D. Allegra,et al.  Radiofrequency Ablation in 447 Complex Unresectable Liver Tumors: Lessons Learned , 2003, Annals of Surgical Oncology.

[16]  W. Cliby,et al.  Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. , 2009, Gynecologic oncology.

[17]  U. Neumann,et al.  Clinical outcome of patients with advanced ovarian cancer after resection of liver metastases. , 2012, Anticancer research.

[18]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[19]  M. Harkenrider,et al.  Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer , 2016, International Journal of Gynecologic Cancer.

[20]  S. Dima,et al.  Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit , 2015, World Journal of Surgical Oncology.

[21]  M. Salzberg,et al.  Current Concepts of Treatment Strategies in Advanced or Recurrent Ovarian Cancer , 2005, Oncology.

[22]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[23]  S. Curley,et al.  Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies. , 2003, Surgical oncology clinics of North America.

[24]  Xiao-Yan Xie,et al.  Percutaneous thermal ablation of medium and large hepatocellular carcinoma: Long-term outcome and prognostic factors , 2008 .

[25]  C. Rossi,et al.  Distant metastases in ovarian carcinoma , 2002, International Journal of Gynecologic Cancer.

[26]  K. Lee,et al.  The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. , 2009, Gynecologic oncology.

[27]  B. Karlan,et al.  Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. , 1999, Gynecologic oncology.